ADTX Aditxt, Inc.

Nasdaq aditxt.com


$ 0.41 $ 0.00 (0 %)    

Friday, 17-Oct-2025 05:46:00 EDT
QQQ $ 592.68 $ 0.00 (0 %)
DIA $ 455.92 $ 0.00 (0 %)
SPY $ 653.91 $ 0.00 (0 %)
TLT $ 91.57 $ 0.00 (0 %)
GLD $ 399.27 $ 0.00 (0 %)
$ 0.4216
$ 0.48
$ 0.41 x 234
$ 0.42 x 16
-- - --
$ 0.42 - $ 297.50
3,064,235
na
886,077
$ 2.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-18-2024 09-30-2024 10-Q
5 08-19-2024 06-30-2024 10-Q
6 05-20-2024 03-31-2024 10-Q
7 04-16-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 04-17-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

-- Special Meeting to be held on September 26, 2025 --SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders tod...

 aditxt-plans-fda-submission-for-first-in-human-trials-in-type-1-diabetes-and-stiff-person-syndrome-in-early-2026

Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for e...

 aditxt-unveils-bitxbio-its-bitcoin-backed-treasury-strategy

Plan Combines Bitcoin Treasury Strategy and Equity Line to Support 2026 Potential Monetization Events, Starting with Pearsanta&...

 aditxt-files-prospectus-related-to-resale-of-up-to-50m-shares-co-may-issue-and-sell-to-seven-knots-from-time-to-time

https://www.sec.gov/Archives/edgar/data/1726711/000121390025056288/ea0246242-s1_aditxt.htm

 aditxts-pearsanta-receives-irb-approval-from-wcg-clinical-to-initiate-prospective-clinical-study-evaluating-mitomic-endometriosis-test-plans-to-begin-patient-enrollment-in-may-2025

Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a potent...

 aditxt-says-mayo-clinic-pre-clinical-studies-further-validates-findings-of-adi-100-adimunes-lead-therapeutic-candidate-for-autoimmune-diseases

Findings Further Support the Safety Profile and Immunomodulatory Effects of ADI-100, Adimune's Lead Therapeutic Candidate f...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION